Trials and Fibrillations with Dr John Mandrola

Are Fish Oils on the Hook for AF Risk? Some studies of fish oil supplements have shown a higher risk for atrial fibrillation with marine omega-3 fatty acids. Is it real? What are the implications for patients taking these capsules?
Experts And Viewpoints, August 10, 2023
Is the Field of Electrophysiology Stuck? The 2023 Heart Rhythm Society meeting featured hot topics such as pulsed-field ablation and late-breaking "trials" on conduction system pacing, but the data gave this electrophysiologist pause.
Experts And Viewpoints, June 01, 2023
ACC/WCC 2023 Three Surprising Studies on Exercise Can exercise be harmful? Studies from the American College of Cardiology on vigorous exercise in people with genetic heart disease and endurance exercise in middle-aged men lend more insight.
Experts And Viewpoints, March 09, 2023
ACC/WCC 2023 Transcatheter Tricuspid Repair Trial: Positive but No Benefit? Can you tell if a procedure improves quality of life without a sham control? John Mandrola, MD, sees a fatal flaw in the TRILUMINATE trial on transcatheter edge-to-edge repair of the tricuspid valve.
Experts And Viewpoints, March 05, 2023
ACC/WCC 2023 Positives and Cautions With Bempedoic Acid for Statin Intolerance Bempedoic acid was effective for reducing CV outcomes in high-risk patients intolerant to statins, but doctors should still discuss the nocebo effect or cheaper alternatives first, says John Mandrola, MD.
Experts And Viewpoints, March 04, 2023
ACC/WCC 2023 5 Things to Look for at ACC 23 Potential new lipid drugs, sports cardiology, and pulsed field ablation are among the topics that piqued Dr John Mandrola's interest at the 2023 American College of Cardiology Scientific sessions.
Experts And Viewpoints, February 27, 2023
Could a HFpEF Breakthrough Just Take a Change of Pace? In heart failure with preserved ejection fraction, a slower heart rate is presumed to help, but a new study suggests that thinking is wrong.
Experts And Viewpoints, February 10, 2023
Five Thoughts on the Damar Hamlin Collapse The cardiac arrest of Buffalo Bills defensive back Damar Hamlin has led to speculation about commotio cordis and more, but one electrophysiologist sees an opportunity for education on CPR and AEDs.
Experts And Viewpoints, January 05, 2023
Mandrola’s Top 10 Cardiology Stories of 2022 A few dogmas felled, wins for meds, an exemplary trial, and clinical trends good and bad are covered in John Mandrola’s annual wrap up of cardiology stories for 2022.
Experts And Viewpoints, December 15, 2022
AHA 2022 STRONG HF: More Beats Less After Discharge for Heart Failure Rapid uptitration of meds after hospitalization for decompensated HF was associated with a reduction in death or hospitalizations. Can health systems do the intense early management, asks John Mandrola, MD.
Experts And Viewpoints, November 08, 2022
AHA 2022 Is Iron Replacement in Heart Failure Worth the Trouble? The data from IRONMAN don't persuade this cardiologist that the additional burden outpatient iron infusions would place on patients with heart failure and low iron are worth it.
Experts And Viewpoints, November 07, 2022
AHA 2022 HCTZ vs Chlorthalidone -- A Win for Practicing Doctors and Science In the Diuretic Comparison Project, hydrochlorothiazide held its own compared with chlorthalidone as first-line hypertension agent despite U.S. experts' preference for the latter -- a lesson for us all, writes John Mandrola, MD.
Experts And Viewpoints, November 05, 2022
Mandrola's Top 5 Picks From AHA 2022 Previewed John Mandrola, MD, previews his top 5 presentations from the upcoming American Heart Association Scientific Sessions in Chicago. They cover diuretics, iron therapy, early ablation, and CRISPR gene editing.
Experts And Viewpoints, October 31, 2022
TCT 2022 Neutral Trial, Positive Spin: PROTECTED TAVR The primary endpoint was negative for a trial of embolic protection during transcatheter aortic valve replacement, yet the paper's conclusion emphasized the potential benefit.
Experts And Viewpoints, September 23, 2022
ESC 2022 Judicious CVD Screening May Work in Men: DANCAVAS Comprehensive cardiac screening in men over 65 years seemed to be of benefit but the Danish setting may be key, writes John Mandrola, MD. Would U.S. screeners be as conservative with their interventions?
Experts And Viewpoints, September 02, 2022
ESC 2022 PCI Fails in Stable Disease Again: REVIVED-BCIS Yet another null finding for stenting in stable patients leads this cardiologist to wonder whether the next generation of cardiologists will end the sclerotic clogged-pipe frame of treating atherosclerosis.
Experts And Viewpoints, August 28, 2022
ESC 2022 Do SGLT2 Inhibitors DELIVER in All Heart Failure? The investigators of the DELIVER trial and others suggest that all patients with heart failure get SGLT2 inhibitors, but this cardiologist sees differing effects depending on ejection fraction.
Experts And Viewpoints, August 27, 2022
ESC 2022 CAPLA Challenges Expert Opinion on Ablation of Persistent AF A trial presented at the European Society of Cardiology teaches that less is more in ablation for persistent AF and reminds clinicians to demand data before adopting aggressive procedures
Experts And Viewpoints, August 26, 2022
ESC 2022 Mandrola Previews His Top 5 Trials From ESC 2022 Dr John Mandrola gives some insight on his choices for important trials to look for at this weekend's European Society of Cardiology Congress in Barcelona
Experts And Viewpoints, August 22, 2022
Medical Necessity vs Therapeutic Fashion How will the sharp eye of history view the procedures and tests we routinely do? Could better critical appraisal sort the medically necessary from those that will eventually fall out of fashion?
Experts And Viewpoints, July 18, 2022

No Results